Sensei Biotherapeutics, Inc. (SNSE)
| Market Cap | 17.45M +134.6% |
| Revenue (ttm) | n/a |
| Net Income | -184.46M |
| EPS | -145.28 |
| Shares Out | 1.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,062 |
| Open | 11.00 |
| Previous Close | 10.79 |
| Day's Range | 11.00 - 13.12 |
| 52-Week Range | 5.60 - 36.76 |
| Beta | -0.23 |
| Analysts | Strong Buy |
| Price Target | 52.50 (+303.85%) |
| Earnings Date | Aug 4, 2026 |
About SNSE
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in ea... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SNSE stock is "Strong Buy." The 12-month stock price target is $52.5, which is an increase of 303.85% from the latest price.
News
Sensei Biotherapeutics initiated with a Buy at BTIG
BTIG initiated coverage of Sensei Biotherapeutics (SNSE) with a Buy rating and $55 price target The clinical-stage biotech company is advancing PIKTOR, a dual oral drug regimen consisting of serabelis...
Sensei Biotherapeutics Registration statement: Registration filing
Sensei Biotherapeutics filed a registration statement on June 10, 2026, providing details about a securities offering with the SEC.
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employ...
Sensei Biotherapeutics Registration statement: Registration filing
Sensei Biotherapeutics filed a registration statement on June 2, 2026, providing details about a securities offering with the SEC.
Sensei Biotherapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Sensei Biotherapeutics (SNSE) with an Overweight rating and no price target Sensei Biotherapeutics is advancing its lead program PIKTOR, an oral PI3Kalpha and m...
Sensei Biotherapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Sensei Biotherapeutics (SNSE) with an Overweight rating.
Sensei Biotherapeutics initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Sensei Biotherapeutics (SNSE) with a Buy rating and $50 price target Sensei is a clinical-stage biotechnology company developing Piktor in second-line advanced endo...
Sensei Biotherapeutics Proxy statement: Proxy filing
Sensei Biotherapeutics filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Sensei Biotherapeutics initiated with a Buy at Citi
Citi initiated coverage of Sensei Biotherapeutics (SNSE) with a Buy rating and $55 price target The company is advancing piktor in endometrial cancer, with second-line adjusted peak sales potential of...
Sensei Biotherapeutics Proxy statement: Proxy filing
Sensei Biotherapeutics filed a proxy statement on May 21, 2026, providing details for shareholder voting and corporate governance matters.
Sensei Biotherapeutics reports Q1 EPS ($131.45) vs ($5.45) last year
“The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of…
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of...
Sensei Biotherapeutics Quarterly report: Q1 2026
Sensei Biotherapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Sensei Biotherapeutics Earnings release: Q1 2026
Sensei Biotherapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Sensei Biotherapeutics announces first patient dosed in FTH-PIK-101 trial
Sensei Biotherapeutics (SNSE) announced that the first patient was dosed in Study FTH-PIK-101, a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigationa...
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Pha...
Sensei Biotherapeutics files to sell 24.87M shares of common stock for holders
07:25 EDT Sensei Biotherapeutics (SNSE) files to sell 24.87M shares of common stock for holders
Sensei Biotherapeutics Registration statement: Registration filing
Sensei Biotherapeutics filed a registration statement on April 28, 2026, providing details about a securities offering with the SEC.
Sensei Biotherapeutics Proxy statement: Proxy filing
Sensei Biotherapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Sensei Biotherapeutics Proxy statement: Proxy filing
Sensei Biotherapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Sensei Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Faeth presented updates on its multi-node cancer metabolism strategy, highlighting strong efficacy and safety data for its oral PIKTOR regimen in endometrial, ovarian, and breast cancers. Key data readouts are expected in 2026–2027, with a focus on expanding indications and maintaining a robust patent position.
Sensei Biotherapeutics Proxy statement: Proxy filing
Sensei Biotherapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16...
Sensei Biotherapeutics Slides: Corporate presentation
Sensei Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Sensei Biotherapeutics reports FY25 EPS ($16.72) vs ($24.01) last year
“2025 was a year of focus and discipline for Sensei, and with the addition of Faeth and injection of new capital, we are entering 2026 with a clear path forward,”…